The detection and quantification of monoclonal-proteins (M-proteins) are necessary for the diag- Particularly, serum FLC has been widely used to aid the diagnosis and management of MM patients and other plasma cell disorders.
| I N T R O D U C T I O N
The presence of monoclonal immunoglobulin (M-protein) in serum or urine, because of an abnormal plasma cell proliferation, is relatively frequent, being detected in approximately 3% of the general adult population (> 50 years) 1 and in up to 7% of subjects seeking medical evaluation. 2 Some of the recognized malignant plasma cell proliferative disorders include multiple myeloma (MM), Waldenstr€ om's macroglobulinemia, asymptomatic monoclonal gammopathy of undetermined significance (MGUS), and premalignant condition such as smoldering multiple myeloma. 3 Other diseases of the same type but with lower tumor burden are light chain (AL) amyloidosis, light chain deposition disease and POEMS syndrome (polyneuropathy, organomegaly, endocrinopahy, monoclonal gammopathy, and skin changes). The approach of hematologists to a patient with M-protein is mainly guided by concerns regarding the size of the B-cell clone responsible for secreting the M-protein. However, M-proteins present at low concentration can have significant pathology-as in the case of AL amyloidosis and POEMS syndrome. Currently, monoclonal gammopathies are screened using a combination of the following three serum-based diagnostic tests in order to maximize screening sensitivity: protein electrophoresis (PEL), immunofixation electrophoresis (IFE), and measurement of free light-chain (FLC). 4, 5 In screening context, this combination negates the need for 24-h urine studies for diagnoses other than AL amyloidosis. 5, 6 Particularly, serum FLC has been widely used to aid the diagnosis and management of MM patients and other plasma cell disorders. [7] [8] [9] We recently developed several mass spectrometry (MS) based methods to detect/measure M-proteins, in serum and urine, with a higher analytical sensitivity and specificity. [10] [11] [12] [13] [14] One method combines nanobody enrichment of immunoglobulins with matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS) in order to achieve rapid identification of M-proteins. The feasibility of using this MALDI-TOF-MS assay (also called MASS-FIX)
to detect M-proteins was demonstrated for both serum and urine. 15, 16 MASS-FIX assay was also shown to provide M-protein quantitative information equivalent to either PEL or the Hevylite assay. In addition, MASS-FIX was shown to be a cost effective M-protein screening method with the same sensitivity of IFE and to be capable of replacing PEL in a screening algorithm. MASS-FIX analyses were done on the same MALDI-TOF mass spectrometer used for bacterial identification in our microbiology laboratory, and institutions that have adopted this technique, could easily explore MASS-FIX to determine suitability for their practice. In addition, with automation, labor costs could become substantially less. 15 The purpose of this study was to compare serum and urine MASS-FIX to the five standard tests (PEL and IFE of both serum and urine and serum FLC ratios) for the identification of M-proteins in different clinical contexts. We intend to demonstrate that MASS-FIX assay can advance how plasma cell disorders are screened, diagnosed, and monitored. [17] [18] [19] Organ involvement of AL patients in the cohort was evaluated as previously reported. 20 Baseline demographics and clinical and laboratory data were recorded for all patients.
| M E T H O D S

| Laboratory analysis
The serum and urine PEL, IFE, and serum FLC measurements were performed within 48 hour of the sample collection. The serum PEL assay was performed on the SPIFE 3000 electrophoresis analyzer (Helena Laboratories). An abnormal serum PEL was defined by the presence of a quantifiable M-spike, fuzzy band, hypogammaglobulinemia Binding Site) was performed on a BNII nephelometer (Siemens). In addition to reporting the j and k FLC concentration, the assay reports the FLC j/k ratio (diagnostic range 0.26-1.65), 21 and an abnormal FLC result was defined as an abnormal FLC j/k ratio. In patients with renal failure, we considered the diagnostic range of 0.37-3.1, as previously reported. 22 Urine samples were concentrated to a maximum of 
| Data analysis
JMP 10.0.0 (SAS Institute) software package was used for all statistical analyses. Patient demographic, clinical and laboratory data were subjected to descriptive statistical analysis. Differences in diagnostic sensitivity were tested for statistical significance by Fishers' exact test, and confidence intervals were determined using exact binomial distribution. Table 1 shows the clinical characteristics of the patient cohort. Of the 290 patients, 257 had all the five conventional tests available.
| R E S U L T S
Twenty-three (25%) of 90 MM patients were newly diagnosed. Of the 65 AL/AH amyloidosis patients, 61 had systemic AL amyloidosis, three patients had a localized AL amyloidosis, and one patient had AH amyloidosis. Of the 61 systemic AL subjects, 26 (42%) were newly diagnosed, 39 (64%) had k light chain in their amyloid deposits, 33 (54%) had heart involvement, 32 (52%) had renal involvement, and 16 (26%)
had more than two organs involved. Fifty-eight patients in cohort had MGUS diagnosis. Of the 31 patients that were classified as "other", 19
(61%) had renal failure (defined as a serum creatinine of 2 mg/dL) without a previous history of any plasma cell dyscrasia. None of these subjects were on chronic dialysis at the time of MASS-FIX evaluation.
Five patients of the "other" group were evaluated for a suspected but not-confirmed systemic AL amyloidosis, and seven patients had non-AL amyloidosis. In particular, five patients were diagnosed with wild-type transthyretin amyloidosis (wtATTR), one patient with mutated-ATTR, and one patient had leucocyte chemotactic factor 2 amyloidosis (ALECT2). The "other plasma cell dyscrasia" group was In the entire cohort, the analytical sensitivity of MASS-FIX of both serum and urine for the comparison with the all the tests available 
| Identification of M-protein in treatment naïve patients by MASS-FIX
We compared the diagnostic sensitivity of MASS-FIX assay in detecting a M-protein with that of PEL, IFE, and FLC (Table 2 and Figure 1 ). was disagreement on the presence of additional less-abundant clones.
| Specific characteristics of MASS-FIX spectra
The mass/charge (m/z) distributions of LC spectra were visually inspected for the presence of a mass shifted peak that was distinct from the expected polyclonal LC m/z region ( Figure 2A ). Both Fifty-one patients had atypical spectral patterns with mass shifted LC peaks, which correspond to posttranslational modifications ( Figure   2 ). In 26 (63%) of samples, the M-protein was detected in both serum and urine. Forty-six percent the cases of the abnormal peaks were kappa LC. In these cases, the abnormal pattern was present in both samples (serum and urine) and it was possible to detect a comparable m/z range of the abnormal peaks. By analyzing samples by diagnosis, a striking pattern emerged. Thirty-two patients had a diagnosis of systemic AL amyloidosis, seven were affected by MM (one patients was newly diagnosed), seven were MGUS, and five patients had other diseases (two patients with a suspected but not confirmed diagnosis of AL amyloidosis, two patients with renal failure and a previously unde- 
| DISCUSSION
Serum IFE, PEL, and FLC combined with urine PEL and IFE offers the most comprehensive panel to screen for monoclonal gammopathies.
This is the first report that evaluates the feasibility of a new screening panel that uses mass spectrometry to detect M-proteins (MASS-FIX) present in paired serum and urine samples. Previous studies demonstrated the importance of using different assay combinations to assess the correct screening strategy and follow-up evaluation according to different diagnoses. 9 MASS-FIX has the potential to be more informative than current methodologies that provide M-protein detection, isotype, isotype specific kappa to lambda heavy light ratios (HLC), and quantitative information with equivocal or improved analytical characteristics. 23 In this report, we found that MASS-FIX was able to identify yield the highest diagnostic sensitivity. 6, 9 Likewise, combined MASS-FIX of serum and urine missed M-protein in only 2 out of the 27 newly diagnosed systemic AL amyloidosis patients. In our study, it is important to note that the MASS-FIX analysis of the urine was performed without concentrating the sample, which provides time and cost savings over u-PEL/u-IFE and also leaves ample room for improvement.
As previously reported by our group, 11 mass spectrometric analysis of LCs using neat urine has similar sensitivity to IFE using concentrated urine sample. The results of our study showed, as previously reported, 15, 16 that the use of only one test could overcome the use of different tests and lead to a significant cost savings, also in different clinical settings. The automation of these technique that will be available soon, will implement the method and also allow an increased reduction of the expense of the entire process. This is the first report to use MASS-FIX on patients with reduced glomerular filtration rate. We found that the m/z of the monoclonal light chain in the urine is not altered in renal failure as compared to that of the serum, making this assay a helpful tool for measuring light chains either in the serum or urine in patients with renal failure. It is well recognized that it is a challenge to know whether patients with renal failure/impairment are truly in complete response based on blood and urine studies. In a recent study, Palladini and colleagues demonstrated that the diagnostic sensitivity of the j/k FLC ratio was lower for lambda amyloidgenic FLC in patients with renal failure (81% vs. 60%). 24 The possibility of obtaining a specific m/z value that could be related with the single M-protein of a specific patient is a great tool in the follow-up management. In addition, our observations regarding the characteristics of the m/z range that is not modified in the urine evaluation, compared to serum, and also in presence of renal failure, could One of the most interesting observations of these analyses was the identification of higher rates of atypical mass spectra among patients with AL amyloidosis by MASS-FIX analysis-nearly 50% of patients with AL amyloidosis had atypical spectra by MASS-FIX. Upon further study using a mass spectrometer with higher resolution and better mass measurement, we observed that one-third of AL amyloidosis patients had monoclonal light chains that were either glycated or glycosylated. Glycosylation has been previously reported in some AL amyloidosis patients. 14, 25 In particular, it was previously showed that glycosylation of AL associated proteins is four times more frequent than reported for light chain from patients with myeloma without amyloidosis. 26 These modifications were found to be present in both kappa and lambda light chains precursor and may predispose fibril formation.
These data are too preliminary to delineate sensitivity and specificity for MASS-FIX and/or ESI-TOF-based PTM analysis for predicting AL, but it is compelling to note that the non-AL patients who had ESI-TOFdefined PTM type patterns included two MGUS patients, who had an incomplete evaluation to exclude of AL (ie no biopsy of target organheart in one and nerve in the other case) and recently diagnosed MM patients who could be at risk for AL amyloidosis over time.
In conclusion, our findings confirmed our previous observation about the high diagnostic ability of MASS-FIX in detection and isotyping M-proteins in both serum and urine. Most importantly, we demonstrate that performance of the assay works across the spectrum of plasma cell disorders and in patients with renal failure. In a subset of treated patients with AL amyloidosis, MASS-FIX revealed minimal residual clonal light chains that IFE and FLC did not but were suspected since these patients were experiencing on-going, progressive organ dysfunction.
Further studies are warranted to confirm these findings and to assess the role of MASS-FIX in detecting minimal residual disease. Finally, further studies are ongoing to confirm the role of MASS-FIX and ESI in the detection of post-translational modifications of clonal light chains and to better define the pathologic impact of these modifications.
